Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

30 Jan 2015
Change (% chg)

$0.06 (+0.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ALKS.O


Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures... (more)


Beta: 1.12
Market Cap(Mil.): $10,565.23
Shares Outstanding(Mil.): 146.23
Dividend: --
Yield (%): --


  ALKS.O Industry Sector
P/E (TTM): -- 188.86 38.54
EPS (TTM): -0.29 -- --
ROI: -2.68 -1.23 18.06
ROE: -3.62 -3.07 18.83
Search Stocks

UPDATE 1-Alkermes schizophrenia drug meets main goal in mid-stage trial

(Adds details, stock movement) (Adds details, share move)

07 Jan 2015

Alkermes schizophrenia drug meets main goal in mid-stage trial

Jan 7 - Alkermes Plc said its experimental drug to treat schizophrenia met the main goal in a mid-stage trial.

07 Jan 2015


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks